The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder that mimics the clinical and laboratory findings of inherited von Willebrand disease (VWD) but occurs in individuals with no previous personal or family history of bleeding. The main pathogenic mechanism is the accelerated removal of von Willebrand factor (VWF) from plasma, due to different causes such as the increased proteolytic degradation of VWF, its adsorption onto malignant cells or activated platelets or to immunoglobulins against the VWF-factor VIII (FVIII) complex. 1 The syndrome is associated with lymphoproliferative, myeloproliferative, cardiovascular and autoimmune diseases and cancer, and is more often occurring in the elderly. 2 The first case of AVWS secondary to systemic lupus erythematosus (SLE) was reported by Simone et al 3 in 1968. Although this association is infrequently described in literature, 1,3,4 even less frequent is its presentation with clinical and laboratory features resembling a severe VWD phenotype. 5 Most cases have mild to moderate bleeding tendency, with laboratory characteristics similar to inherited VWD type 1. 1, 6, 7 The differential diagnosis between AVWS and VWD might be difficult because the personal history of bleeding (acquired or lifelong) is not always conclusive and the two diseases share similar laboratory results. A potential diagnostic biomarker, the ratio of the VWF propeptide (VWFpp) to VWF antigen (VWF:Ag) (VWFpp/ VWF:Ag), is an indicator of an enhanced VWF clearance. 8-10 Only 20% of patients with AVWS have autoantibodies inactivating VWF activity, indicating that mixing tests such as the Bethesda assay may be often inadequate to detect antibodies. 11 A tool that might be useful to confirm the laboratory diagnosis of AVWS is the ELISA that detects anti-VWF non-neutralizing antibodies. 11 Here, we report the case of a severe AVWS secondary to a previously undiagnosed SLE, the main laboratory features over time and the positive clinical and laboratory effect of immunosuppressive therapy. The patient was a 19 years old girl admitted to the emergency room with spontaneous gum bleeding and general malaise. The initial laboratory evaluation showed a prolonged activated partial thromboplastin time (aPTT), with a ratio of 1.51 (normal range 0.86-1.20). Haemoglobin was 10.3 g/dL (normal range 12.0-16.0 g/dL), platelet count 147 000/ μL (normal range 130 000-400 000/μL), aspartate aminotransferase 47 U/L (normal range 10-33 U/L), alanine aminotransferase 108 U/L (normal range 6-41 U/L). The day after admission, the patients also declared to have suffered in the most recent past of easy bruising and heavy menstrual bleeding, but she had no lifelong personal and family history of bleeding. The laboratory assessment revealed a pattern resembling a severe form of VWD, with very low plasma values of factor VIII (FVIII), VWF:Ag, VWF ristocetin cofactor activity (VWF:RCo) (Table 1, Baseline) and a barely detectable VWF multimeric pattern. The tests for hepatitis C and B viruses were negative. Since the patient reported a significant bleeding history only in recent times, an AVWS was hypothesized and the laboratory evaluation was guided by this hypothesis. At baseline the VWFpp/ VWF:Ag was 54 (normal range 0.6-1.6), indicating a normal pro-VWF synthesis but a markedly increased plasma clearance of this moiety, as typical of AVWS. Mixing test with the Bethesda method, using the VWF:RCo and VWF:CB assays, showed the presence of a mild inhibitor against VWF:RCo (1 BU).The syndrome was confirmed by the normal intraplatelet VWF content, but the ELISA for anti-VWF antibodies demonstrated a high titre of IgG and also the presence of IgM (Table 1). Further laboratory investigations revealed the presence of high titre antinuclear antibody (1:1280, normal value <1:60), anti-native DNA antibody (1:40, normal value <1:10) and anti-double-stranded DNA antibody (311 IU/mL, normal range 0-27), some consumption of the complement fractions C3 and C4, mild anaemia and thrombocytopenia. Because these laboratory findings, together with other clinical manifestations such as muscle and joint pain, led to a novel diagnosis of SLE, she started an immunosuppressive daily treatment with prednisone 50 mg, azathioprine 100 mg and hydroxychloroquine sulphate 200 mg. After 2 weeks, a progressive increase in FVIII and VWF values with concomitant reduction in the titre of anti-VWF IgG/IgM antibodies was observed. At the follow-up (FU) day 168 the patient showed a normalization of FVIII and VWF values, and the anti-VWF IgG and IgM antibodies titre became undetectable (Table) . The titre of anti-double-stranded DNA antibody decreased from 311 to 55 IU/mL and the C3 and C4 complement fraction and beta2-microglobulin became normal. A possible explanation of an AVWS secondary to SLE is the increased VWF clearance due to an anti-VWF antibody. The enhanced VWF clearance in our patient was confirmed by the markedly increased VWFpp/VWF:Ag values. By following up the patient over time, a decrease in the VWFpp/VWF:Ag was observed, along with the normalization of VWF measurements that occurred one month after the beginning of the immunosuppressive therapy. The baseline results of the VWFpp/VWF:Ag measurement facilitated the differential diagnosis between VWD and AVWS, and evaluation over time confirmed the efficacy of the immunological treatment and the remission of the underlying disease, previously undiagnosed. 12 It has been already reported that the eradication of the autoantibodies with an aggressive
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The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder that mimics the clinical and laboratory findings of inherited von Willebrand disease (VWD) but occurs in individuals with no previous personal or family history of bleeding. The main pathogenic mechanism is the accelerated removal of von Willebrand factor (VWF) from plasma, due to different causes such as the increased proteolytic degradation of VWF, its adsorption onto malignant cells or activated platelets or to immunoglobulins against the VWF-factor VIII (FVIII) complex. 1 The syndrome is associated with lymphoproliferative, myeloproliferative, cardiovascular and autoimmune diseases and cancer, and is more often occurring in the elderly. 2 The first case of AVWS secondary to systemic lupus erythematosus (SLE) was reported by Simone et al 3 in 1968 . Although this association is infrequently described in literature, 1, 3, 4 even less frequent is its presentation with clinical and laboratory features resembling a severe VWD phenotype. 5 Most cases have mild to moderate bleeding tendency, with laboratory characteristics similar to inherited VWD type 1. 1, 6, 7 The differential diagnosis between AVWS and VWD might be difficult because the personal history of bleeding (acquired or lifelong) is not always conclusive and the two diseases share similar laboratory results. A potential diagnostic biomarker, the ratio of the VWF propeptide (VWFpp) to VWF antigen (VWF:Ag) (VWFpp/ VWF:Ag), is an indicator of an enhanced VWF clearance. [8] [9] [10] Only 20% of patients with AVWS have autoantibodies inactivating VWF activity, indicating that mixing tests such as the Bethesda assay may be often inadequate to detect antibodies. 11 A tool that might be useful to confirm the laboratory diagnosis of AVWS is the ELISA that detects anti-VWF non-neutralizing antibodies. 11 Here, we report the case of a severe AVWS secondary to a previously undiagnosed SLE, In conclusion, we described herein a rare case of severe AVWS secondary to SLE. When the differential diagnosis between AVWS and VWD is challenging, the use of VWFpp/VWF:Ag and the ELISA for the detection of anti-VWF antibodies may facilitate the diagnosis. Also, the successful treatment points out the importance of a therapy aimed at resolving the underlying disease and therefore the acquired bleeding syndrome.
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